Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 4, 2012, Pages 243-251

  Evans Axelsson, Susan ^a   Ulmert, David ^a,b   Örbom, Anders ^a   Peterson, Pernilla ^a   Nilsson, Olle ^c   Wennerberg, Johan ^a   Strand, Joanna ^a   Wingårdh, Karin ^a   Olsson, Tomas ^a   Hagman, Zandra ^a   Tolmachev, Vladimir ^d   Bjartell, Anders ^a   Lilja, Hans ^a,b   Strand, Sven Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FUJIREBIO INC   (Japan)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

digital autoradiography; dual isotope imaging; free PSA; prostate cancer; prostate specific antigen; Radioimmunodetection

Indexed keywords

EPITOPE; FLUORODEOXYGLUCOSE F 18; IODINE 125; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; AUTORADIOGRAPHY; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; CHOLINE; FEASIBILITY STUDIES; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS;

EID: 84862102969     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1088     Document Type: Article

References (49)

1. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: How they are changing the management of prostate cancer. Eur Urol 2011;59: 6.
2. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007; 243: 1.
3. Olsburgh J, Desouza RM. Re: Igle J De Jong, Anthonius JBreeuwsma and Jan Prium. Positron emission tomography in urology. EAU-EBU update series 2007;5: 93.
4. Eur Urol 2007; 52: 1271.
5. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [C-11] choline uptake in prostate cancer: A PET stydy. Eur J Nucl Med Mol Imaging 2004;31: 317.
6. Liu Y. FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. World J Surg Oncol 2008;6: 64.
7. Gutman F, Aflalo-Hazan V, Kerrou K, et al. 18F-choline PET/CT for initial staging of advanced prostate cancer. AJR Am J Roentgenol 2006;187: W618.
8. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296: 580.
9. Fuccio C, Rubello D, Castellucci P, et al. Choline PET/CT for prostate cancer: Main clinical applications. Eur J Radiol 2011; 80: e50.
10. Müller SA, Holzapfel K, Seidl C, et al. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009;36: 1434.
11. Jadvar H, Gurbuz A, Li XK, et al. Choline autoradiography of human prostate cancer xenograft: Effect of castration. Mol Imaging 2008;7: 147.
12. de Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with C-11-choline positron emission tomography. Eur Urol 2002;42: 18.
13. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake of [C-11]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32: 668.
14. Maeda T, Tateishi U, Komiyama M, et al. Distant metastasis of prostate cancer: Early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/ computed tomography in two cases. Jpn J Clin Oncol 2006;36: 598.
15. Schillaci O, Calabria F, Tavolozza M, et al. 18F-choline PET/ CT physiological distribution and pitfalls in image interpretation: Experience in 80 patients with prostate cancer. Nucl Med Commun 2010;31: 39.
16. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8: 268.
17. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505.
18. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37: 1618.
19. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755.
20. Pettersson K, Piironen T, Seppala M, et al. Free and complexed prostate-specific antigen (PSA)-in-vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha (1)-antichymotrypsin complex. Clin Chem 1995; 41: 1480.
21. Bruun L, Ekberg H, Bjork T, et al. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol 2004; 171: 1432.
22. Pizzo SV, Mast AE, Feldman SR, et al. In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta 1988;967: 158.
23. Kilic S, Yalcinkaya S, Guntekin E, et al. Determination of the site of metabolism of total, free, and complexed prostatespecific antigen. Urology 1998;52: 470.
24. Bjork T, Ljungberg B, Piironen T, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998; 51: 57.
25. Lilja H, Haese A, Bjork T, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. JUrol 1999;162: 2029; discussion 2034.
26. Dillman RO, Beauregard J, Ryan KP, et al. Radioimmunodetection of cancer with the use of indium-111- labeled monoclonal antibodies. NCI Monogr 1987: 33.
27. Perala-Heape M, Vihko P, Pelkonen I, et al. Effect of conjugation on the biodistribution of 111In-labelled anti-PAP and anti-PSA monoclonal antibodies examined in nude mice with PC-82 human tumor xenografts. In Vivo 1991; 5: 159.
28. Babaian RJ, Murray JL, Lamki LM, et al. Radioimmuological imaging of metastatic prostatic cancer with indium-111-labeled monoclonal-antibody PAY-276. J Urol 1987;137: 439.
29. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62(5, Suppl1): 27.
30. Baumgart Y, Otto A, Schafer A, et al. Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to alpha 2- macroglobulin. Clin Chem 2005;51: 84.
31. Piironen T, Villoutreix BO, Becker C, et al. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Sci 1998;7: 259.
32. Nilsson O, Peter A, Andersson I, et al. Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Br J Cancer 1997; 75: 789.
33. Stenman UH, Paus E, Allard WJ, et al. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20 (Suppl1): 1.
34. Fernandez-Sanchez C, Gallardo-Soto AM, Rawson K, et al. Quantitative impedimetric immunosensor for free and total prostate specific antigen based on a lateral flow assay format. Electrochem Commun 2004;6: 138.
35. Lövgren T, Leivo P, Pettersson K. In: Vaheri A, Tilton RC, Balows A, eds., Rapid Methods and Automation in Microbiology and Immunology. Berlin: Springer-Verlag, 1990;84-95.
36. Schumann K, Szegner B, Kohler B, et al. A method to assess 59Fe in residual tissue blood content in mice and its use to correct 59Fe-distribution kinetics accordingly. Toxicology 2007;241: 19.
37. Lundwall A, Clauss A, Olsson AY. Evolution of kallikreinrelated peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol Chem 2006;387: 243.
38. Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 1989;XIX: 309.
39. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12: 29.
40. Holland JP, Divilov V, Bander NH, et al. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51: 1293.
41. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009;324: 787.
42. Sanchez D, Rosell D, Honorato B, et al. Androgen receptor mutations are associated with Gleason score in localized prostate cancer. BJU Int 2006;98: 1320.
43. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65: 271.
44. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 2008;60: 1407.
45. Pellegrino D, Bonab AA, Dragotakes SC, et al. Inflammation and infection: Imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med 2005;46: 1522.
46. Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/ CT in the diagnosis and management of prostate cancer. Oncology 2007;72: 226.
47. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med 2008;33: 308.
48. Pascali G, D'Antonio L, Bovone P, et al. Optimization of automated large-scale production of [(18)F]fluoroethylcholine for PET prostate cancer imaging. Nucl Med Biol 2009; 36: 569.
49. Fujimori K, Covell DG, Fletcher JE, et al. A modeling analysis of monoclonal antibody percolation through tumors: Abinding-site barrier. J Nucl Med 1990;31: 1191.